Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Inhibition of Rat Liver Microsomal CYP1A2 and CYP2B1 Activity by N-(2-Heptyl)-N-methyl-propargylamine and by N-(2-Heptyl)-propargylamine

L. E. Dyck and B. A. Davis
Drug Metabolism and Disposition August 2001, 29 (8) 1156-1161;
L. E. Dyck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. A. Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

(R)-N-(2-Heptyl)-N-methyl-propargylamine (R-2HMP) and (R)-N-(2-heptyl)-propargylamine (R-2HPA) are analogs of R-deprenyl.R-Deprenyl, a selective monoamine oxidase B inhibitor, is a mechanism-based inactivator of purified CYP2B1. The aim of the present study was to determine whether R-2HMP andR-2HPA behaved like deprenyl with respect to inhibiting cytochrome P450 (CYP450) enzyme activity. The activities of CYP1A2 and CYP1A1 were assessed by measuring the deethylation of 7-ethoxyresorufin by liver microsomes obtained from control and β-naphthoflavone-treated female Wistar rats, respectively. CYP2B1 activity was assessed by measuring depentylation of 7-pentoxyresorufin by liver microsomes obtained from phenobarbital-treated rats. The activity of CYP1A1 was unaffected by 100 μM concentrations ofR-deprenyl, R-2HMP, orR-2HPA. In contrast, the activities of CYP1A2 and CYP2B1 were significantly decreased. In general, the percentage of CYP1A2 activity remaining in the presence of 100 μM of one of these propargylamines ranged from 45 to 56%, whereas 10% or less of CYP2B1 activity remained. No marked differences between the various propargylamines were observed. The IC50 values for the inhibition of CYP2B1 activity by R-deprenyl,R-2HMP, and R-2HPA were found to be 2.6, 8.5, and 3.6 μM, respectively. The S-enantiomers of deprenyl, 2HMP, and 2HPA also inhibited the activity of microsomal CYP2B1. R-2HMP, R-2HPA, andS-2HPA were found to be mechanism-based inactivators of CYP2B1 activity. The inactivation constantskinact and KIwere found to be as follows: R-deprenyl, 1.3 μM and 0.32 min−1; R-2HMP, 0.8 μM and 0.08 min−1; R-2HPA, 0.5 μM and 0.36 min−1; and S-2HPA, 0.24 μM and 0.18 min−1.

Footnotes

  • ↵1 Alviva Biopharmaceuticals, Inc., Suite 218, 111 Research Dr., Saskatoon, Saskatchewan, Canada S7N 3R2.

  • Saskatchewan Health provided financial support for this study.

  • Abbreviations used are::
    CYP450
    cytochrome P450
    ROS
    reactive oxygen species
    R-2HMP
    (R)-N-2-heptyl-N-methyl-propargylamine
    R-2HPA
    (R)-N-2-heptylpropargylamine
    ANF
    α-naphthoflavone
    BNF
    β-naphthoflavone
    DMSO
    dimethyl sulfoxide
    R-2HMA
    (R)-N-2-heptyl-N-methylamine
    R-2HA
    (R)-N-2-heptylamine
    R-2HPcAc
    (R)-N-2-heptylaminopropionic acid
    PB
    phenobarbital
    ln
    natural log
    • Received December 28, 2001.
    • Accepted May 8, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 29 (8)
Drug Metabolism and Disposition
Vol. 29, Issue 8
1 Aug 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of Rat Liver Microsomal CYP1A2 and CYP2B1 Activity by N-(2-Heptyl)-N-methyl-propargylamine and by N-(2-Heptyl)-propargylamine
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inhibition of Rat Liver Microsomal CYP1A2 and CYP2B1 Activity by N-(2-Heptyl)-N-methyl-propargylamine and by N-(2-Heptyl)-propargylamine

L. E. Dyck and B. A. Davis
Drug Metabolism and Disposition August 1, 2001, 29 (8) 1156-1161;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Inhibition of Rat Liver Microsomal CYP1A2 and CYP2B1 Activity by N-(2-Heptyl)-N-methyl-propargylamine and by N-(2-Heptyl)-propargylamine

L. E. Dyck and B. A. Davis
Drug Metabolism and Disposition August 1, 2001, 29 (8) 1156-1161;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Human ADME Properties of Abrocitinib
  • MSCs Pharmacokinetics under liver diseases
  • OATP1B Downregulation in CDCA-Treated Monkeys
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics